Inventor · disambiguated record
Patricia Busca
Also filed as: BUSCA PATRICIA
2 granted patents·5 pending applications·4 citations·filing 2015–2023
53Inventor score
Files withINST NAT SANTE RECH MED4INSTITUT NATIONAL DE LA SANTE ET DE LE RECH MEDICALE INSERM1NSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE INSERM1UNIV PARIS CITE1
Top patents by PatentIndex Score
7 records- 0184US2024350490A1Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3INST NAT SANTE RECH MED·Filed 2023·Application pending·0 cites
- 0282US9931341B2Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3INST NAT SANTE RECH MED·Filed 2015·Granted Apr 3, 2018·2 cites·1 claims
- 0381US11357778B2Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3INSTITUT NATIONAL DE LA SANTE ET DE LE RECH MEDICALE INSERM·Filed 2019·Granted Jun 14, 2022·2 cites·1 claims
- 0474US2023075776A1Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3INST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 0558US2018161327A1Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3NSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE INSERM·Filed 2018·Application pending·0 cites
- 0645US2025108029A1Inhibitors of the interaction between the rock and pdk1 protein kinasesUNIV PARIS CITE·Filed 2022·Application pending·0 cites
- 0730US2018237424A1Fgfr3 antagonistsINST NAT SANTE RECH MED·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Patricia Busca files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →